



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Tracy Myhill**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 16<sup>th</sup> January 2020  
Ein Cyf / Our Ref: 19-L-012

☎ 01639 648363  
✉ FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 13<sup>th</sup> December 2019. Your request sought information relating to treatment of breast and urothelial cancer patients.

Please note that the information below covers the period of September, October and November 2019.

**1. Within your health board how many patients are currently [within the past 3 months] being treated with the following for breast cancer?**

**Abemaciclib + aromatase inhibitor \*** - We are unable to split Abemaciclib patients – total of 10 patients on all combinations of Abemaciclib.

**Abemaciclib + Fulvestrant** - See above

**Alpelisib + Fulvestrant** - 0

**Atezolizumab** - 0

**Bevacizumab** - 0

**Eribulin** - <5

**Everolimus + Exemestane** - 6 patients on Everolimus – Exemestane is not prescribed so unable to provide a combined figure.

**Fulvestrant as a single agent** - 19

**Gemcitabine + paclitaxel** - 0

**Lapatinib** - 0



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

**Neratinib** - 0

**Olaparib** - 0

**Palbociclib + aromatase inhibitor\*** - 39 patients on Palbociclib – aromatase inhibitors are not prescribed so unable to provide a combined figure.

**Pertuzumab + trastuzumab + docetaxel** - 12

**Ribociclib + aromatase inhibitor\*** Unable to split Ribociclib patients – total of 2 patients on all combinations of Ribociclib

**Ribociclib + Fulvestrant** - See above

**Talazoparib** - 0

**Herceptin SC** - 68

**Herceptin IV** - 0

**Transtuzumab biosimilar SC** - 0

**Transtuzumab biosimilar IV** - <5

**Trastuzumab emtansine** - <5

**Other active systemic anti-cancer therapy \*\*** - 58

**\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

**\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent**

## **2. How many patients are being treated for:**

### **2a Neo-adjuvant breast cancer;**

**Transtuzumab total SC** - 20

**Transtuzumab total IV** - 0

### **2.b Adjuvant breast cancer;**

**Transtuzumab total SC** - 0

**Transtuzumab total IV** - <5

## **3. In the past 3 months, how many Urothelial cancer patients were treated with;**

**Atezolizumab** - <5

**Carboplatinum in combination with another agent** - <5

**Carboplatinum single agent** - 0

**Cisplatinum in combination with another agent** - <5

**Cisplatinum single agent** - 0

**Nivolumab** - 0

**Pembrolizumab** - 0



**Any other chemo regimen without cisplatinum or carboplatinum - 0**

**Other active systemic anti-cancer therapy [please state] - 0**

**Palliative care only** – This information is not held centrally on our systems\*.

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

\*To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

